HALF BETA-PROGRANE Sustained release capsule Ref.[49926] Active ingredients: Propranolol

Beta-Prograne 160 mg Sustained-Release Capsules or Half Beta-Prograne 80 mg Sustained-release Capsules as with other beta-adrenoceptor blocking drugs:

• although contra-indicated in uncontrolled heart failure (see section 4.3) may be used in patients whose signs of heart failure have been controlled. Caution must be exercised in patients whose cardiac reserve is poor.
• heart failure due to thyrotoxicosis often responds to propranolol alone, but if other adverse factors co-exist myocardial contractility must be maintained and signs of failure controlled with digitalis and diuretics.
• should not be used in combination with calcium channel blockers with negative inotropic effects (e.g. verapamil, diltiazem), as it can lead to an exaggeration of these effects particularly in patients with impaired ventricular function and/or SA or AV conduction abnormalities. This may result in severe hypotension, bradycardia and cardiac failure. Neither the beta-blocker not the calcium channel blocker should be administered intravenously within 48 hours of discontinuing the other.
• beta-blockers may increase the number and duration of anginal attacks in patients with Prinzmetal’s angina, due to unopposed alpha-receptor mediated coronary artery vasoconstriction. Non-selective beta-blockers, such as propranolol, should not be used in patients with Prinzmetal’s angina and beta-1 selective agents should be used with care (see section 4.3).
• in patients with peripheral circulatory disorders (Raynaud’s disease or syndrome, intermittent claudication), beta-blockers should be used with great caution as aggravation of these disorders may occur. Although contra-indicated in severe peripheral arterial circulatory disturbances (see section 4.3) may also aggravate less severe peripheral arterial circulatory disturbances.
• due to its negative effect on conduction time, caution must be exercised if it is given to patients with first degree heart block.
• may block/modify the signs and symptoms of the hypoglycaemia (especially tachycardia). Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80 mg Sustained-Release Capsules occasionally causes hypoglycaemia, even in non-diabetic patients, e.g., neonates, infants, children, elderly patients, patients on haemodialysis or patients suffering from chronic liver disease and patients suffering from overdose. Severe hypoglycaemia associated with Beta-Prograne 160 mg Sustained-release Capsules and Half-Beta-Prograne 80 mg Sustained-Release Capsules has rarely presented with seizures and/or coma in isolated patients. Caution must be exercised in the concurrent use of Beta-Progane 160 mg Sustained-Release Capsules and Half Beta-Prograne 80 mg Sustained-Release Capsules and hypoglycaemic therapy in diabetic patients. Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80 mg Sustained-Release Capsules may prolong the hypoglycaemic response to insulin (see section 4.3).
• may mask the signs of thyrotoxicosis.
• should not be used in untreated phaeochromocytoma. However, in patients with phaeochromocytoma, an alpha-blocker may be given concomitantly.
• should be used to treat the elderly with caution starting with a lowest possible dose (see section 4.2).
• will reduce heart rate as a result of its pharmacological action. In the rare instances, if the pulse rate decreases to below 50-55 beats per minute at rest, when a treated patient develops symptoms that may be attributable to a slow heart rate, the dose may be reduced.
• may cause a more severe reaction to a variety of allergens, when given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline used to treat the allergic reactions.

Abrupt withdrawal of beta-blockers is to be avoided. The dosage should be withdrawn gradually over a period of 7 to 14 days. An equivalent dosage of another beta-blocker may be substituted during the withdrawal period to facilitate a reduction in dosage below Half Beta-Prograne 80 mg Sustained-Release Capsules. Patients should be followed during withdrawal especially those with ischaemic heart disease.

Anaesthesia: As with all beta-adrenoceptor blocking drugs it may be decided to withdraw Beta-Prograne before surgery. In this case 24-48 hours should be allowed to elapse between the last dose and anaesthesia. If treatment is continued care should be taken when using anaesthetic agents which cause myocardial depression such as cyclopropane and trichloroethylene, which are best avoided. Anaesthetics may cause attenuation of the reflex tachycardia and increase the risk of hypotension. Continuation of beta-blockade reduces the risk of arrhythmia during induction and intubation. The anaesthesiologist should be informed when the patient is receiving a beta-blocking agent. Vagal dominance, if it occurs, may be corrected with atropine (1-2 mg I.V.).

The risk/benefit of stopping beta blockade should be made for each patient.

Since the half-life may be increased in patients with significant hepatic or renal impairment, caution must be exercised when starting treatment and selecting the initial dose.

Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80mg Sustained-Release Capsules must be used with caution in patients with decompensated cirrhosis (see section 4.2).

In patients with portal hypertension, liver function may deteriorate and hepatic encephalopathy may develop. There have been reports suggesting that treatment with propranolol may increase the risk of developing hepatic encephalopathy (see section 4.2).

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Patients with rare hypersensitivity for sulphur dioxide should not take this medicine; which may cause hypersensitivity reactions and bronchospasm.

Patients with a history of wheezing or asthma should not take propranolol unless it is considered essential. The product label states the following warning: “Do not take Beta-Prograne 160 mg Sustained-Release Capsules if you have a history of asthma or wheezing”. A similar warning appears in the Patient Information Leaflet.

Bronchospasm can usually be reversed by beta2 agonist bronchodilators such as salbutamol. Large doses of the beta2 agonist bronchodilator may be required to overcome the beta blockade produced by propranolol and the dose should be titrated according to the clinical response; both intravenous and inhalational administration should be considered. The use of intravenous aminophylline and/or the use of ipratropium (given by nebuliser) may also be considered. Glucagon (1 to 2 mg given intravenously) has also been reported to produce a bronchodilator effect in asthmatic patients. Oxygen or artificial ventilation may be required in severe cases.

Intolerance to propranolol, shown as bradycardia and hypotension may occur, in which case propranolol should be withdrawn. If necessary, treatment for overdose should be started.

Interference with laboratory tests

Beta-Prograne 160 mg Sustained-release Capsules or Half Beta-Prograne 80 mg Sustained-Release Capsules have been reported to interfere with the estimation of serum bilirubin by the diazo method and with the determination of catecholamines by methods using fluorescence.

Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80 mg Sustained-Release Capsules modify the tachycardia of hypoglycaemia. Caution must be exercised in the concurrent use of Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80 mg Sustained-Release Capsules and hypoglycaemic therapy in diabetic patients. Propranolol may prolong the hypoglycaemic response to insulin (see section 4.3 and 4.4).

Simultaneous administration of rizatriptan and propranolol can cause an increased rizatriptan AUC and C_max by approximately 70-80%. The increased rizatriptan exposure is presumed to be caused by inhibition of first-passage metabolism of rizatriptan through inhibition of monoamine oxidase-A. If both drugs are to be used, a rizatriptan dose of 5mg has been recommended.

Caution must be exercised when prescribing a beta-adrenoceptor blocking drug with Class 1 antiarrhythmic agents such as disopyramide and amiodarone (may have potentiating effect on atrial-conduction time and induce negative inotropic effect).

Digitalis glycosides, e.g. digitoxin or digoxin taken at the same time as beta-blockers can increase atrioventricular conduction time.

There is an increased risk of myocardial depression and bradycardia, there is also an increased risk of lidocaine toxicity. The antidysrhythmic propafenone increases plasma concentration of propranolol.

Combined use of beta-adrenoceptor blocking drugs and calcium channel blockers with negative inotropic effects e.g. verapamil, diltiazem, can lead to an exaggeration of these effects, particularly in patients with impaired ventricular function and/or sino-atrial or atrio-ventricular conduction abnormalities. This may result in severe hypotension, bradycardia and cardiac failure. Neither the beta-adrenoceptor blocking drug nor the calcium channel blocker should be administered intravenously within 48 hours of discontinuing the other.

Concomitant therapy with dihydropyridine calcium channel blockers e.g. nifedipine, may increase the risk of hypotension, and cardiac failure may occur in patients with latent cardiac insufficiency.

Concomitant use of sympathomimetic agents, e.g. adrenaline, may counteract the effect of beta-adrenoceptor blocking drugs. Caution must be exercised in the parenteral administration of preparations containing adrenaline to patients taking beta- adrenoceptor blocking drugs as, in rare cases, vasoconstriction, hypertension and bradycardia may result.

Administration of propranolol during infusion of lidocaine may increase the plasma concentration of lidocaine by approximately 30%. Patients already receiving propranolol tend to have higher lignocaine levels than controls. The combination should be avoided.

Monoamine oxidase inhibitors, excepting MAO-B inhibitors.

Concomitant use of cimetidine and hydralazine will increase the plasma levels of propranolol. Fluvoxamine taken with propanol also has this effect. Concomitant use of alcohol may increase the plasma levels of propranolol and enhances hypotensive effect.

Beta-adrenoceptor blocking drugs may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are co-administered, the beta-adrenoceptor blocking drug should be withdrawn several days before discontinuing clonidine. If replacing clonidine by beta-adrenceptor blocking drug therapy, the introduction of beta-adrenoceptor blocking drugs should be delayed for several days after clonidine administration has stopped.

Caution must be exercised if ergotamine, dihydroergotamine or related compounds are given in combination with propranolol since vasospastic reactions have been reported in a few patients.

Concomitant use of prostaglandin synthetase inhibiting drugs, e.g. ibuprofen or indometacin, may decrease the hypotensive effects of propranolol.

Tricyclic antidepressants, barbiturates, phenothiazines and other medicines used to reduce blood pressure – may increase the blood pressure-lowering effect of propranolol.

Concomitant administration of propranolol and chlorpromazine may result in an increase in plasma levels of both drugs. This may lead to an enhanced antipsychotic effect for chlorpromazine and an increased antihypertensive effect for propranolol.

Concomitant administration of rifampicin with propranolol may result in reduced plasma concentrations of propranolol. Thyroxine taken at the same time as propranolol also has this effect.

ACE inhibitors and Angiotensin-II Antagonists taken at the same time as propranolol may result in enhanced hypotensive effects. Aldesleukin and Alprostadil also has this effect.

Concomitant administration of corticosteroid may result in antagonism of hypotensive effect.

Beta blockers including propranolol when taken with moxisylyte may result in severe postural hypotension

Concomitant administration of muscle relaxants may result in enhanced hypotensive effect.

Oestrogen and progestrogens, as used in the contraceptive pill, when taken with propranolol may antagonise the hypotensive effect.

The manufacturer of tropisetron advises caution for the co-administration with propranolol.

The concomitant administration of xamoterol with propranolol may result in a reduction in the beta-blockade.

Parasympathomimetics when used with propranolol increase the possibility of arrhythmias.

Caution must be exercised when using anaesthetic agents with Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80 mg Sustained-Release Capsules. The anaesthetist should be informed and the choice of anaesthetic should be the agent with as little negative inotropic activity as possible. Use of beta-adrenoceptor blocking drugs with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.

Interference with laboratory test

Propranolol has been reported to interfere with the estimation of serum bilirubin by the diazo method and with the determination of catecholamines by methods using fluorescence.

Pharmacodynamic studies have shown that the following agents may interact with propranolol due to effects on enzyme systems in the liver which metabolise propranolol and these agents: quinidine (increased risk of myocardial depression and bradycardia), propafenone, rifampicin, theophylline, warfarin, thioridazine and dihydropyridine calcium channel blockers such as nifedipine, nisoldipine, nicardipine, isradipine and lacidipine. Owing to the fact that blood concentrations of either agent may be affected, dosage adjustments may be needed according to clinical judgement, (see also the interaction above concerning therapy with dihydropyridine calcium channel blockers).

Pregnancy

As with all drugs, Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80 mg Sustained-Release Capsules should not be given during pregnancy unless their use is essential. There is no evidence of teratogenicity.

However beta-adrenoceptor blocking drugs reduce placental perfusion, which may result in intra-uterine foetal death, immature and premature deliveries. In addition, adverse effects (especially hypoglycaemia and bradycardia in the neonate and bradycardia in the foetus) may occur. There is an increased risk of cardiac and pulmonary complications in the neonate in the post-natal period.

Breastfeeding

Most beta-adrenoceptor blocking drugs particularly lipophilic compounds, will pass into breast milk although to a variable extent. Breast feeding is therefore not recommended following administration of these compounds.

The use of Beta-Prograne 160 mg Sustained-Release Capsules or Half Beta-Prograne 80 mg Sustained-Release Capsules is unlikely to result in any impairment of the ability of patients to drive or operate machinery.

However, when driving vehicles or operating machines it should be taken into account that occasionally dizziness or fatigue may occur. If so, the patient should not drive or operate machines.

Beta-Prograne 160 mg Sustained-Release Capsules and Half Beta-Prograne 80mg Sustained-Release Capsules are usually well tolerated. In clinical studies, the undesired events reported are usually attributable to the pharmacological actions of propranolol.

Adverse reactions frequency is defined using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare(≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Discontinuance of the drug should be considered if, according to clinical judgement, the well being of the patient is adversely affected by any of the above reactions. Cessation of therapy with a beta-adrenoceptor blocking drug should be gradual. In the rare event of intolerance manifested as bradycardia and hypotension, the drug should be withdrawn and, if necessary, treatment for overdosage instituted.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the yellow card scheme at: www.mhra.gov.uk/yellowcard.

None known.